Stanley Thornton, MD
Interventional Cardiology · Mobile, ALNPI 1588870224
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,418 of the $7,243 with a category attached, or 88.6%. 26 manufacturers reported payments, led by Medtronic at 48.6% of the total. 2025 is the largest year on record at $1,646, 2.6 times the $632 reported in 2019.
Across 183 payments — averaging $39.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$1K
- Edwards Lifesciences$646
- Canon Medical Systems USA, Inc.$373
- Philips North America LLC$261
- Boston Scientific$183
- plus $1K from 20 others
Across 12 payments — averaging $1277.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$11K
- Surmodics, Inc.$2K
- Boston Scientific$2K
What the payments were for
- Consulting fees$130%
- Travel & lodging$81211%
- Food & beverage$6,41889%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 93 | $3,523 |
| Abbott | 12 | $1,164 |
| Edwards Lifesciences | 9 | $646 |
| Canon Medical Systems USA, Inc. | 2 | $373 |
| Philips North America LLC | 5 | $261 |
| Boston Scientific | 8 | $183 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $137 |
| Penumbra, Inc. | 4 | $118 |
| Cardiva Medical, Inc. | 4 | $113 |
| Johnson & Johnson | 8 | $112 |
| Boehringer Ingelheim | 4 | $77 |
| Abiomed | 2 | $74 |
| Getinge USA Sales, LLC | 2 | $57 |
| Novartis | 3 | $56 |
| Osprey Medical Inc | 2 | $51 |
| Pfizer | 3 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Shockwave Medical, Inc | 2 | $41 |
| Biocompatibles, Inc. | 1 | $37 |
| Amgen | 2 | $31 |
| Cardiovascular Systems Inc. | 2 | $26 |
| Terumo Medical Corporation | 1 | $15 |
| Reflow Medical Inc | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Z-medica, LLC | 1 | $13 |
| Argon Medical Devices, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,243 in reported general payments places this provider in the 55th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 337 | $356,840 |
| Repatha SureclickEvolocumab | 184 | $138,957 |
| EntrestoSacubitril/Valsartan | 106 | $110,885 |
| XareltoRivaroxaban | 42 | $64,837 |
| JardianceEmpagliflozin | 15 | $16,420 |
| Praluent PenAlirocumab | 26 | $12,763 |
| Dofetilide | 33 | $12,636 |
| Atorvastatin Calcium | 496 | $5,907 |
| Prasugrel Hcl | 47 | $5,025 |
| Metoprolol Succinate | 275 | $3,862 |
| Rosuvastatin Calcium | 187 | $3,143 |
| ClopidogrelClopidogrel Bisulfate | 241 | $2,688 |
| Carvedilol | 219 | $2,043 |
| Omega-3 Acid Ethyl Esters | 16 | $2,033 |
| Potassium Chloride | 91 | $1,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $49 | $356,840337 claims |
| NovartisEntresto | $56 | $110,885106 claims |
| Johnson & JohnsonXarelto | $112 | $64,83742 claims |
| Boehringer IngelheimJardiance | $77 | $16,42015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Mobile
- John GallaMobile$82K
- Ahmed SubahiMobile$37K
- Mir HashimiMobile$24K
- Mohammed ElzeneiniMobile$23K
- Benjamin CitrinMobile$11K
- James GladdenMobile$9K
- Michael MonsonMobile$7K
- Kevin DeandradeMobile$7K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.